Once-Daily Dasatinib for Treatment of Patients with Chronic Myeloid Leukemia

Nilotinib in patients with imatinib-resistant or -intolerant chronic myelogenous leukemia in chronic phase (CML-CP): Updated phase II results

(2017) H. M. Kantarjian et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib or high-dose imatinib for patients with chronic myelogenous leukemia chronic-phase (CML-CP) resistant to standard- dose imatinib: 2-year follow-up data from START-R

(2017) P. H. Rousselot et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure

(2017) A. Hochhaus et al.   JOURNAL OF CLINICAL ONCOLOGY

Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

(2017) P. le Coutre et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C)

(2017) M. J. Mauro et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib pharmacokinetics and exposure-response (E-R): Relationship to safety and efficacy in patients (pts) with chronic myeloid leukemia (CML)

(2017) X. Wang et al.   JOURNAL OF CLINICAL ONCOLOGY

Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia

(2008) K. Porkka et al.   BLOOD

Sprycel for Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Resistant to or Intolerant of Imatinib Mesylate

(2008) M. Brave et al.   CLINICAL CANCER RESEARCH

Metabolism and Disposition of Dasatinib after Oral Administration to Humans

(2008) L. J. Christopher et al.   DRUG METABOLISM AND DISPOSITION

Hemolysis-associated hypercoagulability in sickle cell disease: the plot (and blood) thickens!

(2008) M. T. Gladwin et al.   HAEMATOLOGICA

Reply to: Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008; 93:e11-13

(2008) L. Charnas et al.   HAEMATOLOGICA

Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia

(2008) Neil P. Shah et al.   JOURNAL OF CLINICAL ONCOLOGY